Suchergebnisse - "Spira, Alexander"

PubPharm (169)

1

A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors : phase 1 trial interim results

enthalten in: Nature medicine | 2024

von Rappaport, A. | Kyi, C. | Lane, M. | +35

2

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer : Results From the Phase I TROPION-PanTumor01 Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Bardia, A. | Krop, I. | Kogawa, T. | +17

3

Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer : A Case Series and Literature Review

enthalten in: JCO precision oncology | 2024

von Luo, J. | Florez, N. | Donnelly, A. | +6

4

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

enthalten in: Cancer medicine | 2024

von Juric, D. | Barve, M. | Vaishampayan, U. | +19

5

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

enthalten in: Blood advances | 2024

von Hamadani, M. | Spira, A. | Zhou, X. | +16

6

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

enthalten in: Cancer Medicine | 2024

von Juric, D. | Barve, M. | Vaishampayan, U. | +19

7

Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer

enthalten in: The New England journal of medicine | 2023

von Heymach, J. | Harpole, D. | Mitsudomi, T. | +125

CommentIn: N Engl J Med. 2024 Jan 18;390(3):287. - PMID 38231634

8

Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer : The Phase II NeoCOAST Platform Trial

enthalten in: Cancer discovery | 2023

von Cascone, T. | Kar, G. | Spicer, J. | +25

CommentIn: Cancer Discov. 2023 Nov 1;13(11):2306-2309. - PMID 37909090

9

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer : a phase 1 trial

enthalten in: Nature medicine | 2023

von Cho, B. | Kim, D. | Spira, A. | +21

10

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer : TROPION-PanTumor01

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Shimizu, T. | Sands, J. | Yoh, K. | +14

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[17]